New hope for slowing scarring kidney disease
NCT ID NCT07268638
Summary
This study is testing whether an investigational drug called praliciguat can help control focal segmental glomerulosclerosis (FSGS), a disease that causes scarring in the kidneys. About 60 adults with confirmed FSGS will receive either the drug or a placebo for 24 weeks, followed by the drug for everyone for another 24 weeks. The main goal is to see if the drug safely reduces the amount of protein leaking into the urine, which is a key sign of kidney damage.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOCAL SEGMENTAL GLOMERULOSCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Investigator Site # 1
RECRUITINGLawrenceville, Georgia, 30046, United States
-
Investigator Site #2
RECRUITINGChula Vista, California, 91910, United States
-
Investigator Site #3
RECRUITINGChicago, Illinois, 60643, United States
-
Investigator Site #4
RECRUITINGChattanooga, Tennessee, 37404, United States
-
Investigator Site #5
RECRUITINGArlington, Texas, 76015, United States
Conditions
Explore the condition pages connected to this study.